Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Certolizumab pegol | Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Certolizumab pegol | Drug | Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients achieving Psoriasis Area Severity Index 75% response at observational point 2 | The Psoriasis Area Severity Index (PASI75) response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked). | From Baseline up to Week 21 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Dermatology Life Quality Index score at observational point 2 | The Dermatology Life Quality Index (DLQI) consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related quality of life (HRQoL). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not applicable
Not provided
Not provided
Not provided
Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| UCB Cares | 001 844 599 2273 (UCB) | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ps0026 101 | Brussels | Belgium | ||||
| Ps0026 103 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38937404 | Derived | Korge B, Vanhooteghem O, Lynde CW, Machovcova A, Perrussel M, Lazaridou E, Marasca C, Sarro DV, Pousa ID, Fierens F, Williams P, Shimizu S, Heidbrede T, Warren RB. Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study. Dermatol Ther (Heidelb). 2024 Aug;14(8):2077-2092. doi: 10.1007/s13555-024-01210-3. Epub 2024 Jun 27. |
Not provided
Not provided
Data from non-interventional studies is outside of UCB's data sharing policy and is unavailable for sharing.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From Baseline up to Week 21 |
| Change from Baseline in Dermatology Life Quality Index score at observational point 4 | The Dermatology Life Quality Index (DLQI) consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related quality of life (HRQoL). | From Baseline up to Week 56 |
| Percentage of patients achieving Psoriasis Area Severity Index 75% response at observational point 4 | The Psoriasis Area Severity Index (PASI75) response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked). | From Baseline up to Week 56 |
| Percentage of patients achieving Psoriasis Area Severity Index 90% response at observational point 2 | The Psoriasis Area Severity Index (PASI90) response assessments are based on at least 90 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked). | From Baseline up to Week 21 |
| Percentage of patients achieving Psoriasis Area Severity Index 90% response at observational point 4 | The Psoriasis Area Severity Index (PASI90) response assessments are based on at least 90 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked). | From Baseline up to Week 56 |
| Brussels |
| Belgium |
| Ps0026 107 | Brussels | Belgium |
| Ps0026 102 | Leuven | Belgium |
| Ps0026 110 | Maldegem | Belgium |
| Ps0026 109 | Mons | Belgium |
| Ps0026 104 | Namur | Belgium |
| Ps0026 208 | London | Canada |
| Ps0026 209 | London | Canada |
| Ps0026 201 | Markham | Canada |
| Ps0026 210 | Newmarket | Canada |
| Ps0026 203 | St. John's | Canada |
| Ps0026 212 | Toronto | Canada |
| Ps0026 205 | Waterloo | Canada |
| Ps0026 204 | Winnipeg | Canada |
| Ps0026 301 | Prague | Czechia |
| Ps0026 303 | Prague | Czechia |
| Ps0026 302 | Uherské Hradiště | Czechia |
| Ps0026 408 | Amiens | France |
| Ps0026 404 | Lorient | France |
| Ps0026 409 | Poitiers | France |
| Ps0026 403 | Rennes | France |
| Ps0026 407 | Toulon | France |
| Ps0026 512 | Bielefeld | Germany |
| Ps0026 532 | Bogen | Germany |
| Ps0026 525 | Dresden | Germany |
| Ps0026 506 | Düren | Germany |
| Ps0026 521 | Freiburg im Breisgau | Germany |
| Ps0026 529 | Gladbeck | Germany |
| Ps0026 523 | Hamburg | Germany |
| Ps0026 518 | Karlsruhe | Germany |
| Ps0026 519 | Leipzig | Germany |
| Ps0026 537 | Magdeburg | Germany |
| Ps0026 530 | Memmingen | Germany |
| Ps0026 516 | Merzig | Germany |
| Ps0026 517 | München | Germany |
| Ps0026 527 | München | Germany |
| Ps0026 515 | Nuremberg | Germany |
| Ps0026 501 | Potsdam | Germany |
| Ps0026 511 | Quedlinburg | Germany |
| Ps0026 505 | Remscheid | Germany |
| Ps0026 603 | Athens | Greece |
| Ps0026 609 | Athens | Greece |
| Ps0026 610 | Athens | Greece |
| Ps0026 601 | Chaïdári | Greece |
| Ps0026 606 | Larissa | Greece |
| Ps0026 608 | Pátrai | Greece |
| Ps0026 607 | Piraeus | Greece |
| Ps0026 604 | Thessaloniki | Greece |
| Ps0026 605 | Thessaloniki | Greece |
| Ps0026 707 | Bari | Italy |
| Ps0026 714 | Bologna | Italy |
| Ps0026 711 | Brescia | Italy |
| Ps0026 712 | Catania | Italy |
| Ps0026 710 | Florence | Italy |
| Ps0026 702 | Genova | Italy |
| Ps0026 706 | L’Aquila | Italy |
| Ps0026 701 | Naples | Italy |
| Ps0026 709 | Roma | Italy |
| Ps0026 713 | Roma | Italy |
| Ps0026 704 | San Donato Milanese | Italy |
| Ps0026 715 | Torino | Italy |
| Ps0026 708 | Torrette DI Ancona | Italy |
| Ps0026 807 | Badalona | Spain |
| Ps0026 809 | Barcelona | Spain |
| Ps0026 812 | Barcelona | Spain |
| Ps0026 804 | Pontevedra | Spain |
| Ps0026 806 | Sant Joan Despí | Spain |
| Ps0026 818 | Vigo | Spain |
| Ps0026 902 | Bradford | United Kingdom |
| Ps0026 909 | Dunfermline | United Kingdom |
| Ps0026 914 | Glasgow | United Kingdom |
| Ps0026 916 | Hertfordshire | United Kingdom |
| Ps0026 911 | Kingston upon Thames | United Kingdom |
| Ps0026 905 | Leeds | United Kingdom |
| Ps0026 904 | Newcastle upon Tyne | United Kingdom |
| Ps0026 901 | Salford | United Kingdom |
| Ps0026 915 | Wakefield | United Kingdom |
| Ps0026 908 | York | United Kingdom |
| ID | Term |
|---|---|
| D000068582 | Certolizumab Pegol |
| ID | Term |
|---|---|
| D011092 | Polyethylene Glycols |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D007140 | Immunoglobulin Fab Fragments |
| D007128 | Immunoglobulin Fragments |
| D010446 | Peptide Fragments |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided